Healthy volunteers needed to test new version of cancer drug
NCT ID NCT07639905
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new formulation of the cancer drug HRS-2189 in 28 healthy adults aged 18-45. The goal is to compare how the body absorbs the new versus the old tablet version and to check for safety. Participants will take a single dose of each formulation in random order, with a break in between. This study does not aim to treat cancer, but to gather important information for future drug development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230601, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear acupressure: a new weapon against chemotherapy side effects?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?
- Can a new tracer light up tumors better than standard PET scans?
- Personalized weight loss coaching could help cancer survivors shed pounds
- New PET tracer aims to light up tumors, but trial stalls
- New injection aims to fight Cancer-Related wasting